{"id":211129,"date":"2025-09-08T21:25:09","date_gmt":"2025-09-08T21:25:09","guid":{"rendered":"https:\/\/www.europesays.com\/us\/211129\/"},"modified":"2025-09-08T21:25:09","modified_gmt":"2025-09-08T21:25:09","slug":"next-ozempic-aims-to-deliver-30-weight-loss-with-fewer-side-effects","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/211129\/","title":{"rendered":"‘Next Ozempic’ aims to deliver 30% weight loss with fewer side effects"},"content":{"rendered":"

Researchers believe they may have the next, better version of Ozempic<\/a> in the works.<\/p>\n

At Tufts University, scientists have developed a new drug that aims to\u00a0boost weight loss\u00a0while also reducing the nausea, muscle loss, and weight regain associated with popular GLP-1 medications.<\/p>\n

The goal is for the\u00a0\u201cquadruple-action\u201d medication\u00a0to achieve long-lasting weight loss of up to 30% \u2014 matching the effectiveness of bariatric surgery, which reduces the size of the stomach, according to a study press release.<\/p>\n

How the drug is different<\/strong><\/p>\n

Semaglutide medications, like Ozempic and Wegovy<\/a>, mimic the natural hormone GLP\u20111 (glucagon\u2011like peptide\u20111), while tirzepatides (such as Mounjaro and Zepbound) target both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors.<\/p>\n

The new medication from Tufts targets a combination of four hormones \u2014 GLP-1, GIP, glucagon (the counterpart to insulin), and peptide YY, which reduces hunger, slows stomach emptying, and may\u00a0promote fat-burning.<\/p>\n

Researchers believe they may have the next, better version of Ozempic (above) in the works. Christopher Sadowski<\/p>\n

\u201cWe built a single experimental peptide that works like four hormones at once, so we\u2019re not pushing one button too hard,\u201d lead author Tristan Dinsmore, PhD, a researcher at Tufts University, told Fox News Digital.<\/p>\n

\u201cInstead, we\u2019re nudging four \u2018dimmer switches\u2019 together to manage appetite, blood sugar, and energy use.\u201d<\/p>\n

Because GLP\u20111 and PYY can contribute to nausea at higher doses, the researchers relied on GIP, which is known to ease nausea, to \u201cbalance things out,\u201d Dinsmore said.<\/p>\n

The goal is for the\u00a0\u201cquadruple-action\u201d medication\u00a0to achieve long-lasting weight loss of up to 30% \u2014 matching the effectiveness of bariatric surgery, according to a study press release. Getty Images\/iStockphoto<\/p>\n

\u201cBeyond helping with fullness and glucose control, GIP signaling has anti\u2011nausea effects \u2014 it can even block nausea in preclinical models, which is why we prioritize it in the mix,\u201d he went on.<\/p>\n

\u201cBy adding PYY to the GLP\u20111\/GIP\/glucagon trio, we hope to rely less on GLP\u20111 and glucagon to drive weight loss, potentially lowering the chance of nausea (from GLP\u20111\/PYY) and\u00a0high blood sugar\u00a0risk (from glucagon) while keeping the benefits.\u201d<\/p>\n<\/p>\n

The medication is still in the experimental\/preclinical stage and has not yet been tested in human trials.<\/p>\n

The drug\u2019s development was published in the Journal of the American Chemical Society.<\/p>\n

Doctors react<\/strong><\/p>\n

The new medication from Tufts targets a combination of four hormones \u2014 GLP-1, GIP, glucagon (the counterpart to insulin), and peptide YY. Choi_ Nikolai \u2013 stock.adobe.com<\/p>\n

Dr. Brett Osborn, a Florida neurosurgeon and\u00a0longevity expert, is a strong advocate for GLP-1 medications.<\/p>\n

\u201cSingle-agent GLP-1s like Ozempic work for most people,\u201d Osborn, who was not involved in the Tufts study, told Fox News Digital. \u201cSide effects are manageable when an\u00a0experienced physician\u00a0supervises you.\u201d<\/p>\n

\u201cWe don\u2019t need more medications to treat the same chronic problem that has increasingly burdened the world,\u201d he added. \u201cThere are plenty of highly effective GLP-1 agonists right in front of us.\u201d<\/p>\n

The biggest risks with GLP-1s is muscle loss and malnutrition from undereating, he said. To prevent this, the doctor emphasizes the need for adequate daily protein and consistent strength training.<\/p>\n

To treat the \u201cchronic\u201d\u00a0disease of obesity, Osborn recommends microdosing or intermittent dosing of GLP-1s, paired with nutrition, progressive resistance training, hydration, and sleep.\u00a0<\/p>\n

\u201cEssentially, use the medicine that works and combine it with\u00a0disciplined habits,\u201d he advised. \u201cI\u2019ve used this approach for years, as have many of my patients, with excellent long-term tolerance.\u201d<\/p>\n

Sue Decotiis, M.D., a medical weight loss doctor in New York City, noted that\u00a0controlling appetite, enhancing metabolism, and increasing fat burning \u2014 while also balancing the interactions of blood sugar and insulin \u2014 is a \u201ccomplex function.\u201d<\/p>\n

\u201cThe additional mechanisms offered by new drugs may help some, but not necessarily most\u00a0weight-loss\u00a0patients,\u201d Decotiis, who was also not involved in the study, told Fox News Digital.<\/p>\n

\u201cEven with new mechanisms added to weight-loss medications, individual patients will have varied responses in the amount of fat they lose.\u201d\u00a0<\/p>\n

\t\t\t\t\t\t\tStart your day with all you need to know\t\t\t\t\t\t<\/p>\n

\n\t\t\t\t\t\t\tMorning Report delivers the latest news, videos, photos and more.\t\t\t\t\t\t<\/p>\n

\t\t\t\t\t\tThanks for signing up!\n\t\t\t\t<\/p>\n

She noted that her patients who take GLP-1s do not typically experience muscle and bone loss.\u00a0<\/p>\n

\u201cGood care in\u00a0medical weight loss\u00a0should include following patients with a body composition scale and monitoring protein, fiber, and excellent hydration,\u201d she said.<\/p>\n

Limitations and future research<\/strong><\/p>\n

There were some limitations of the new drug, the researchers acknowledged.<\/p>\n

The medication is still in the experimental\/preclinical stage and has not yet been tested in human trials. Getty Images<\/p>\n

\u201cThis is design research that showcases the potential for the next generation and perhaps even tailored drugs,\u201d Dinsmore told Fox News Digital. \u201cOur data come from cell\u2011based assays, not animals or humans (yet).\u201d<\/p>\n

\u201cChoosing the safest, most effective balance of the four pathways will require in vivo (living) studies and\u00a0clinical trials.\u201d<\/p>\n

People using GLP\u20111\u2011based drugs should stick with their clinician\u2019s guidance, Dinsmore advised.<\/p>\n

\u201cGood care in\u00a0medical weight loss\u00a0should include following patients with a body composition scale and monitoring protein, fiber, and excellent hydration,\u201d Sue Decotiis, M.D., a medical weight loss doctor, said. WavebreakMediaMicro \u2013 stock.adobe.com<\/p>\n

\u201cThis is not a medicine you can get today,\u201d he said of the new medication. \u201cOur work is a next\u2011generation concept that aims to improve results and\u00a0reduce nausea\u00a0by spreading the work across four hormones rather than overloading one.\u201d<\/p>\n

Obesity is estimated to affect over 40% of American adults<\/a> and has been linked to dozens of diseases, including type 2 diabetes, heart disease, stroke, sleep apnea,\u00a0high blood pressure,\u00a0and several types of cancer.<\/p>\n

\u201cWhat drives us is the idea that we can design a single drug to treat obesity and simultaneously mitigate the risk of developing a long list of\u00a0health problems\u00a0plaguing society,\u201d said co-study author Krishna Kumar, Robinson Professor of Chemistry at Tufts.<\/p>\n","protected":false},"excerpt":{"rendered":"Researchers believe they may have the next, better version of Ozempic in the works. At Tufts University, scientists…\n","protected":false},"author":3,"featured_media":211130,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[210,1060,10943,427,881,67,132,68,428],"class_list":{"0":"post-211129","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-health","9":"tag-medication","10":"tag-obesity","11":"tag-ozempic","12":"tag-public-health","13":"tag-united-states","14":"tag-unitedstates","15":"tag-us","16":"tag-weight-loss"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/211129","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=211129"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/211129\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/211130"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=211129"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=211129"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=211129"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}